Abstract
The availability of validated mortality data for a wide spectrum of risk classes in a nationally representative US sample1 is 1 advantage of the Lee mortality index over comparable relatively easily applicable comorbidity assessment tools like the age-adjusted Charlson score.2 These mortality figures may be used as a reference scale to compare differently selected prostate cancer samples. At least in the next few years, we will still be forced to draw conclusions from prostate cancer populations (for instance the Prostate Cancer Intervention Versus Observation Trial [PIVOT] population3) that differ partially considerably from advice-seeking patients in the daily practice.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
